Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.612,75
0,19%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Synaptogenix Inc (SNPX) Synaptogenix Inc (SNPX) Notizie

SNPX

Synaptogenix (SNPX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNPX
DataOraFonteTitoloSimboloCompagnia
15/05/202423:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202415:00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202415:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202415:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202414:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202416:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
21/12/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
19/12/202315:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202315:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
14/11/202323:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
13/11/202323:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
03/11/202322:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
02/11/202314:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202315:00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
07/09/202315:00PR Newswire (US)Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyNASDAQ:SNPXSynaptogenix Inc
19/07/202315:00PR Newswire (US)Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
13/07/202315:00PR Newswire (US)Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceNASDAQ:SNPXSynaptogenix Inc
22/06/202323:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
15/05/202322:51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNPXSynaptogenix Inc
31/03/202322:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
21/03/202322:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SNPXSynaptogenix Inc
07/03/202315:00PR Newswire (US)Synaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesNASDAQ:SNPXSynaptogenix Inc
18/01/202322:29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SNPXSynaptogenix Inc
28/12/202222:16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SNPXSynaptogenix Inc
28/12/202212:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SNPXSynaptogenix Inc
16/12/202215:00PR Newswire (US)Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
18/11/202215:00PR Newswire (US)Synaptogenix Announces $15 Million Private Placement with Existing InvestorsNASDAQ:SNPXSynaptogenix Inc
19/10/202215:00PR Newswire (US)Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022NASDAQ:SNPXSynaptogenix Inc
28/09/202217:50PR Newswire (US)Synaptogenix Welcomes Lecanemab Phase 3 Trial ResultsNASDAQ:SNPXSynaptogenix Inc
25/08/202222:34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNPXSynaptogenix Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNPX

La tua Cronologia

ASX
CGFKOG
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network